Parvaresh Laila, Mills Llewellyn, Gholami Jaleh, Jansen Louisa, Jamshidi Nazila, Baker Kate, Tremonti Christopher, Tracy Marguerite, Dunlop Adrian, Lintzeris Nicholas
Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia.
Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Drug Alcohol Rev. 2025 Jul;44(5):1339-1350. doi: 10.1111/dar.14074. Epub 2025 May 5.
There are no prior studies investigating the perspectives of Opioid Treatment Program (OTP) clinicians on clients' cannabis use. This study examines the perspectives of OTP clinicians on patterns of cannabis use; harms and benefits; current and potential interventions and their confidence in implementing them.
Clinicians from six public OTP services in New South Wales completed the survey. Participants included nurses, doctors, pharmacists, allied health and consumer workers. Single-level regression models were used to estimate participants' sex, role and experience effect.
A total of 162 participants responded to the survey (estimated response rate 56%). Participants estimated 56.1% (±23.9) of OTP clients had used cannabis in the past month, and 44.9% (±6.5) had cannabis dependence. Clinicians indicated (15.3% ± 17.2%) clients identified problematic cannabis use and (10.7% ± 16.9) sought treatment in the past year. The harms most frequently identified by staff were cannabis dependence (46.5% ± 27.9%), financial issues (37.5% ± 29.2%) and increased tobacco use (33.1% ± 28.2%). The benefits most frequently identified were management of sleep problems (49.7% ± 27.8%), chronic pain symptoms (35.6% ± 24.3%) and improvements in mental health (48.3% ± 25.6%). Sixty-five participants (63.7%) advocated for enhancing efforts to address cannabis use, with none supporting scaling down services. Clinicians prioritised withdrawal services (81%), harm reduction (77.4%), counselling (74%) and medicinal cannabis (59.8%), although the majority had low confidence in delivering most of these interventions.
Despite awareness about cannabis use patterns and identification of both harms and benefits, clinicians identified low rates of cannabis interventions and low levels of confidence in delivering interventions.
此前尚无研究调查阿片类药物治疗项目(OTP)临床医生对客户使用大麻情况的看法。本研究考察了OTP临床医生对大麻使用模式、危害与益处、当前及潜在干预措施以及他们对实施这些措施的信心。
新南威尔士州六个公共OTP服务机构的临床医生完成了该调查。参与者包括护士、医生、药剂师、专职医疗人员和消费者工作者。采用单水平回归模型来估计参与者的性别、角色和经验效应。
共有162名参与者回复了调查(估计回复率为56%)。参与者估计,在过去一个月中,56.1%(±23.9)的OTP客户使用过大麻,44.9%(±6.5)的客户有大麻依赖。临床医生指出,在过去一年中,(15.3%±17.2%)的客户存在问题性大麻使用情况,(10.7%±16.9)的客户寻求过治疗。工作人员最常指出的危害是大麻依赖(46.5%±27.9%)、财务问题(37.5%±29.2%)和吸烟增加(33.1%±28.2%)。最常指出的益处是睡眠问题的管理(49.7%±27.8%)、慢性疼痛症状(35.6%±24.3%)和心理健康改善(48.3%±25.6%)。65名参与者(63.7%)主张加大力度解决大麻使用问题,无人支持缩减服务。临床医生将戒断服务(81%)、减少危害(77.4%)、咨询(74%)和药用大麻(59.8%)列为优先事项,不过大多数人对提供这些干预措施的信心较低。
尽管了解大麻使用模式并认识到其危害和益处,但临床医生发现大麻干预措施的实施率较低,且对提供干预措施的信心不足。